
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV has positioned itself advantageously in the biotechnology sector through extensive patent protections for its innovative target discovery platforms and antigenic peptide targets, enhancing its competitive edge. The company has demonstrated promising clinical outcomes, specifically a 50% objective response rate and a 6.0 months median progression-free survival in advanced melanoma patients, which considerably surpasses standard-of-care benchmarks. With a revised global risk-adjusted sales forecast of €711.3 million for 2035, Immatics is poised for significant revenue growth driven by its strategic collaborations and effective therapies in oncology.
Bears say
Immatics NV faces significant risks that could adversely impact its financial outlook, including potential setbacks in research and development, regulatory hurdles, and competition from emerging companies. The company's reliance on successful clinical trial outcomes is tempered by the possibility that even if endpoints are met, they may not satisfy regulatory criteria, leading to delays in product approval. Additionally, the necessity for further capital raises poses a risk of share dilution, which could further undermine investor confidence and negatively affect stock performance.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares